Tobias Aw Holderried

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3580441/publications.pdf

Version: 2024-02-01

42 papers

2,296 citations

430874 18 h-index 377865 34 g-index

42 all docs 42 docs citations

times ranked

42

5046 citing authors

#	Article	IF	CITATIONS
1	Ly-6C ^{high} Monocytes Depend on Nr4a1 to Balance Both Inflammatory and Reparative Phases in the Infarcted Myocardium. Circulation Research, 2014, 114, 1611-1622.	4.5	427
2	On-demand erythrocyte disposal and iron recycling requires transient macrophages in the liver. Nature Medicine, 2016, 22, 945-951.	30.7	333
3	Stable inhibitory activity of regulatory T cells requires the transcription factor Helios. Science, 2015, 350, 334-339.	12.6	323
4	Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. Journal of Clinical Investigation, 2005, 115, 1797-1805.	8.2	259
5	Intradermal Vaccinations With RNA Coding for TAA Generate CD8+ and CD4+ Immune Responses and Induce Clinical Benefit in Vaccinated Patients. Molecular Therapy, 2011, 19, 990-999.	8.2	199
6	$E\hat{l}\frac{1}{4}$ - <i>TCL1</i> mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 6250-6255.	7.1	112
7	Innate Response Activator B Cells Aggravate Atherosclerosis by Stimulating T Helper-1 Adaptive Immunity. Circulation, 2014, 129, 1677-1687.	1.6	107
8	Immunomodulatory effects of anti-angiogenic drugs. Leukemia, 2011, 25, 899-905.	7.2	60
9	Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma. Clinical Epigenetics, 2019, 11, 161.	4.1	49
10	Genetic disruption of CD8 ⁺ Treg activity enhances the immune response to viral infection. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 21089-21094.	7.1	41
11	Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy. Oncolmmunology, 2016, 5, e1108511.	4.6	41
12	Disruption of CD8+ Treg Activity Results in Expansion of T Follicular Helper Cells and Enhanced Antitumor Immunity. Cancer Immunology Research, 2014, 2, 207-216.	3.4	38
13	Post-transcriptional regulation of adapter molecules by IL-10 inhibits TLR-mediated activation of antigen-presenting cells. Leukemia, 2009, 23, 535-544.	7.2	34
14	Higher number of multidisciplinary tumor board meetings per case leads to improved clinical outcome. BMC Cancer, 2020, 20, 355.	2.6	33
15	Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia. Blood Cancer Journal, 2021, 11, 164.	6.2	29
16	Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma. Clinical Epigenetics, 2020, 12, 94.	4.1	26
17	The role of checkpoint blockade after allogeneic stem cell transplantation in diseases other than Hodgkin's Lymphoma. Bone Marrow Transplantation, 2019, 54, 1662-1667.	2.4	22
18	Transfection of Dendritic Cells with in Vitro-Transcribed CMV RNA Induces Polyclonal CD8+- and CD4+-Mediated CMV-Specific T Cell Responses. Molecular Therapy, 2006, 13, 280-288.	8.2	21

#	Article	IF	CITATIONS
19	NK Cells Regulate CD8+ T Cell Mediated Autoimmunity. Frontiers in Cellular and Infection Microbiology, 2020, 10, 36.	3.9	20
20	Fecal microbiota transfer for refractory intestinal graftâ€versusâ€host disease â€" Experience from two German tertiary centers. European Journal of Haematology, 2021, 107, 229-245.	2.2	20
21	Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial. Blood, 2021, 138, 463-463.	1.4	19
22	Treatment Response Monitoring in Patients with Advanced Malignancies Using Cell-Free SHOX2 and SEPT9 DNA Methylation in Blood. Journal of Molecular Diagnostics, 2020, 22, 920-933.	2.8	15
23	959â€Safety and anti-tumor activity of TCR-engineered autologous, PRAME-directed T cells across multiple advanced solid cancers at low doses â€" clinical update on the ACTengine® IMA203 trial. , 2021, 9, A1009-A1009.		15
24	Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110069.	2.7	13
25	Characterization of BAX inhibitor-1 as a novel leukemia-associated antigen. Leukemia, 2009, 23, 1818-1824.	7.2	10
26	The Role of Immune Checkpoints after Cellular Therapy. International Journal of Molecular Sciences, 2020, 21, 3650.	4.1	7
27	Immunotherapy in renal cell carcinoma. Immunotherapy, 2009, 1, 97-107.	2.0	5
28	Helios-expressing CD8 ⁺ T cells are decreased in patients with systemic lupus erythematosus. Lupus, 2021, 30, 1022-1024.	1.6	4
29	Selective ABO immunoadsorption in hematopoietic stem cell transplantation with major ABO incompatibility. European Journal of Haematology, 2021, 107, 324-332.	2.2	3
30	CD8+ Treg - From Mouse To Man. Blood, 2013, 122, 3474-3474.	1.4	3
31	FRIO548â€PREVALENCE AND THERAPY OF RHEUMATOLOGICAL ADVERSE EVENTS DUE TO IMMUNE CHECKPOII INHIBITOR THERAPY. Annals of the Rheumatic Diseases, 2020, 79, 875.1-876.	NT 0.9	2
32	Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in AML Patients Shows MRD Conversion and Improved Survival. Blood, 2021, 138, 1274-1274.	1.4	2
33	Conversion from MRD Positive to Negative Status in AML Patients in CR1 after Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine. Blood, 2020, 136, 13-14.	1.4	2
34	ROCKing Chronic Graft-Versus-Host Disease. Journal of Clinical Oncology, 2021, 39, JCO.21.01081.	1.6	1
35	Preliminary Report for the Development of a Multiparameter Protocol for the Identification of Sinusoidal Obstruction Syndrome including Abdominal Ultrasound before and after Allogeneic Stem Cell Transplantation. Applied Sciences (Switzerland), 2022, 12, 829.	2.5	1
36	RefraktÃres/rezidiviertes Multiples Myelom: CAR-T-Zell-Therapie zeigt betrÃrehtliche Wirksamkeit. Karger Kompass Onkologie, 2021, 8, 130-131.	0.0	0

#	Article	IF	CITATIONS
37	Gene Expression Profiling Identifies Similar CD4+ and CD8+ T Cell Defects in TCL1 Transgenic Mice after Development of CLL to Those Observed in Patients with CLL Blood, 2004, 104, 180-180.	1.4	0
38	Cell Contact with CLL Cells Induces Defects in T Cell Differentiation and Effector Pathways: Impact of Silencing Specific Cytokine Production Blood, 2004, 104, 955-955.	1.4	0
39	A Mouse Model for Immunotherapeutic Reversal of Leukemia-Induced T Cell Dysfunction. Blood, 2008, 112, 30-30.	1.4	O
40	Releasing CD8+ Treg Mediated Suppresssion Enhances Anti-Viral Immune Response. Blood, 2013, 122, 2280-2280.	1.4	0
41	Immunotherapy With RNA Vaccination Coding For TAA In Renal Cell Carcinoma: Update On Immunological Responses and Correlation With Survival. Blood, 2013, 122, 1040-1040.	1.4	0
42	Human CD8+ Treg after Allogeneic Stem-Cell Transplantation. Blood, 2016, 128, 2243-2243.	1.4	O